West Pharmaceutical Services, Inc. (WST) News
Follow West Pharmaceutical Services, Inc. (WST) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 44 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
West Pharmaceutical Services Reports Q3 2026 Revenue of $874.5M, EPS of $3.02
Third-quarter net income was $214 million. Revenue increased 8.7% and net income rose 52.9% from the prior-year quarter.
EQUITY | Oct 29, 2026, 08:22 PM UTC
M
West Pharma raises annual forecasts
West Pharma shares rise after the company raises its annual forecasts.
EARNINGS | Oct 29, 2026, 02:46 PM UTC
M
West Pharmaceutical raises full-year outlook
West Pharmaceutical raised its full-year outlook. Its shares rose in morning trading.
EARNINGS | Oct 29, 2026, 02:46 PM UTC
M
West Pharmaceutical Services Reports Quarterly Results
West Pharmaceutical Services reported results for the quarter ended September 30.
EQUITY | Oct 29, 2026, 01:33 PM UTC
M
West Pharma exec says Q3 HVP device growth rate may not repeat in Q4
A West Pharma executive said during a conference call that the Q3 HVP device growth rate is not expected to repeat in Q4.
EARNINGS | Oct 29, 2026, 12:28 PM UTC
M
West Pharma executive says GLP-1 drugs helped drive growth in India and China
A West Pharma executive said GLP-1 drugs helped drive growth in India and China, according to a conference call.
EQUITY | Oct 29, 2026, 12:25 PM UTC
M
West Pharma Executive Says CGM Program Decline Contributed to Q3 Revenue Drop
A West Pharma executive said a decline in the CGM program contributed to a Q3 revenue drop at West Vantage.
EQUITY | Oct 29, 2026, 12:18 PM UTC
M
West Pharma Executive Says Q3 Cyber-Deferred Revenue Fully Recovered
A West Pharma executive said revenue deferred by a cyber incident in Q3 was fully recovered.
EQUITY | Oct 29, 2026, 12:17 PM UTC
M
West Pharma Executive Sees SmartDose 3.5 as 290-Basis-Point 2027 Growth Headwind
A West Pharma executive said SmartDose 3.5 revenue will be about a 290-basis-point headwind to reported growth in 2027.
EARNINGS | Oct 29, 2026, 12:17 PM UTC
M
West Pharma Raises Annual Guidance; Shares Rise
West Pharma shares rose after the company raised its annual forecasts.
EARNINGS | Oct 29, 2026, 11:38 AM UTC
M
West Pharmaceutical Services shares rise after raising annual outlook
West Pharmaceutical Services shares rose after the company raised its annual outlook.
EARNINGS | Oct 29, 2026, 11:38 AM UTC
M
West Pharmaceutical Q3 Adjusted Earnings and Sales Rise, Raises 2026 Outlook
EQUITY | Oct 29, 2026, 10:51 AM UTC
L
West Pharmaceutical Reports Q3 EPS of $3.02
EARNINGS | Oct 29, 2026, 10:28 AM UTC
M
West Pharma sees FY adjusted EPS of $9.38-$9.48
EARNINGS | Oct 29, 2026, 10:14 AM UTC
M
West Pharma Sees FY Sales of $3.41B-$3.42B
EARNINGS | Oct 29, 2026, 10:14 AM UTC
M
West Pharm Beats Q3 EPS by $0.46, Raises FY26 Guidance
West Pharm reported Q3 earnings of $2.66 per share, excluding non-recurring items, $0.46 above expectations. It also beat on revenue and raised FY26 EPS and revenue guidance above consensus.
EARNINGS | Oct 29, 2026, 10:13 AM UTC
M
West Pharmaceutical net profit rises 53% year over year in Q3 2026
EARNINGS | Oct 29, 2026, 10:11 AM UTC
M
West Pharmaceutical Reports Third-Quarter Adjusted EPS of $2.66
EARNINGS | Oct 29, 2026, 10:09 AM UTC
M
West Pharmaceutical sets FY adjusted EPS outlook
The company’s FY adjusted EPS outlook is above the IBES estimate of USD 8.96.
EARNINGS | Oct 29, 2026, 10:02 AM UTC
M
West Reports Third-Quarter 2026 Results
EQUITY | Oct 29, 2026, 10:01 AM UTC
M
West Pharmaceutical provides FY net sales outlook
West Pharmaceutical's FY net sales outlook is stated against the IBES estimate of USD 3,373 million.
EARNINGS | Oct 29, 2026, 10:01 AM UTC
M
West Pharmaceutical Reports 3Q Sales of $874.5 Million
West Pharmaceutical reported third-quarter sales of $874.5 million.
EARNINGS | Oct 29, 2026, 10:01 AM UTC
M
West Pharmaceutical Reports Third-Quarter Net Income of $214 Million
EARNINGS | Oct 29, 2026, 10:01 AM UTC
L
West Pharma Reports Third-Quarter EPS of $3.02
EARNINGS | Oct 29, 2026, 10:01 AM UTC
M
West Pharma shares rise 3.4% after refinancing credit facility
West Pharma shares rose 3.4% in after-hours trading after completing a credit-facility refinancing, according to a regulatory filing.
EQUITY | Oct 26, 2026, 09:46 PM UTC
L
West Pharmaceutical Secures $950 Million Credit Agreement
West Pharmaceutical secured a $950 million credit agreement with lenders led by Bank of America.
EQUITY | Oct 26, 2026, 09:16 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
WST: Raised guidance and margin expansion reflect strong HVP-driven growth and strategic investments
Leadership transition is expected to accelerate growth initiatives and customer engagement. Q2 results beat expectations, prompting raised guidance and margin expansion, driven by HVP components, biologics, and GLP-1s. I
EARNINGS | Sep 10, 2026, 02:10 PM UTC
H
WST: Raised guidance and strong HVP growth highlight robust momentum and strategic investment focus
Leadership transition is expected to accelerate growth, with Q2 results surpassing expectations and full-year guidance raised to 10%-11% growth. HVP components, biologics, and regulatory changes drive momentum, while inv
EARNINGS | Sep 10, 2026, 01:40 PM UTC
L
West Pharma price target raised by UBS; rating kept at Buy
UBS maintained West Pharma at Buy and raised its price target to $415.00 per share from $340.00, according to TradingView News and Benzinga’s ratings action summary.
EQUITY | Sep 09, 2026, 06:13 PM UTC
L
WST - West to Participate in Upcoming Investor Conferences
WST - West to Participate in Upcoming Investor Conferences
EQUITY | Aug 26, 2026, 08:00 PM UTC
H
Westinghouse Submits Draft IPO Registration
Westinghouse files draft IPO registration statement
EQUITY | Jul 31, 2026, 11:23 AM UTC
L
CASY EA EW ESS HON WST session lows
CASY EA EW ESS HON WST session lows
EQUITY | Jul 24, 2026, 04:09 PM UTC
H
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical Services, Inc. (NYSE: WST ) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08.
EARNINGS | Jul 23, 2026, 03:32 PM UTC
H
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call
West Pharmaceutical Servs (NYSE: WST ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earni
EARNINGS | Jul 23, 2026, 01:22 PM UTC
H
WST West Pharmaceutical RESULTS: Q2, Q2 net sales $872.3M vs. EST $838.6M, Q2 EPS $2.15, West Pharmaceutical Earnings Notes:, - West Pharmac
WST West Pharmaceutical RESULTS: Q2, Q2 net sales $872.3M vs. EST $838.6M, Q2 EPS $2.15, West Pharmaceutical Earnings Notes:, - West Pharmaceutical Q2 ADJ EPS $2.37 vs. EST $2.08, Outlook FY net sales $3,345-3.380B vs. E
RATES | Jul 23, 2026, 10:25 AM UTC
L
West Pharmaceutical ups FY26 adjusted EPS view to $9.85-$9.05 from $8.40-$8.75
Consensus $8.62. Raises...
EARNINGS | Jul 23, 2026, 10:14 AM UTC
L
West Pharmaceutical reports Q2 adjusted EPS $2.37, consensus $2.08
Reports Q2 revenue...
EARNINGS | Jul 23, 2026, 10:09 AM UTC
H
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est
West Pharmaceutical Servs (NYSE: WST ) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..
EARNINGS | Jul 23, 2026, 10:08 AM UTC
L
WST - West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
WST - West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
EQUITY | Jul 14, 2026, 08:47 PM UTC
L
WST West Pharmaceutical Services - Co and daikyo seiko enter amended crosslicense and distributorship agreements effective July 14, 2026 - S
WST West Pharmaceutical Services - Co and daikyo seiko enter amended crosslicense and distributorship agreements effective July 14, 2026 - SEC filing West Pharmaceutical Services Inc: Co maintains a 49% ownership interes
REGULATION | Jul 14, 2026, 08:32 PM UTC
H
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
Morgan Stanley raised the firm's price target on West Pharmaceutical to $365 from $325 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 11:01 AM UTC
L
Evercore ISI Adjusts Price Target on West Pharmaceutical Services to $410 From $390
() -- West Pharmaceutical Services (WST) has an average rating of overweight and mean price target of $367.15, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks an
EQUITY | Jul 06, 2026, 01:10 PM UTC
L
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE: WST ) with a Overweight and raises the price target from $350 to $390.
EQUITY | Jul 02, 2026, 01:02 PM UTC